ZEVRA THERAPEUTICS, INC. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2016 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Zevra Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2016 to Q4 2023.
  • Zevra Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending December 31, 2023 was $16.1M, a 124% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $16.1M +$8.93M +124% Dec 31, 2023 10-K 2024-04-01
Q3 2023 $3.1M Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $1.3M Jun 30, 2023 10-Q 2023-08-14
Q4 2022 $7.19M +$5.76M +406% Dec 31, 2022 10-K 2024-04-01
Q4 2021 $1.42M -$1.02M -41.8% Dec 31, 2021 10-K 2023-03-07
Q4 2020 $2.44M +$761K +45.3% Dec 31, 2020 10-K 2022-03-31
Q4 2019 $1.68M +$1.68M Dec 31, 2019 10-K 2021-03-12
Q4 2018 $0 -$2.01M -100% Dec 31, 2018 10-K 2020-02-28
Q1 2018 $1.51M Mar 31, 2018 10-Q 2018-05-11
Q4 2017 $2.01M -$3M -59.9% Dec 31, 2017 10-K 2019-03-01
Q3 2017 $2.5M Sep 30, 2017 10-Q 2017-11-09
Q4 2016 $5M Dec 31, 2016 10-K 2018-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.